These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11271014)

  • 1. The physical and psychosocial consequences of opioid addiction: an overview of changes in opioid treatment.
    Brown R; Lo R
    Aust N Z J Ment Health Nurs; 2000 Jun; 9(2):65-74. PubMed ID: 11271014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
    Simon DL
    Conn Med; 1996 Nov; 60(11):683-5. PubMed ID: 8979434
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 5. Haight-Ashbury free clinics' drug detoxification protocols--Part 2: Opioid blockade.
    Galloway G; Hayner G
    J Psychoactive Drugs; 1993; 25(3):251-2. PubMed ID: 8258763
    [No Abstract]   [Full Text] [Related]  

  • 6. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
    Sigmon SC; Bisaga A; Nunes EV; O'Connor PG; Kosten T; Woody G
    Am J Drug Alcohol Abuse; 2012 May; 38(3):187-99. PubMed ID: 22404717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can psychotherapy rescue naltrexone treatment of opioid addiction?
    Rounsaville BJ
    NIDA Res Monogr; 1995; 150():37-52. PubMed ID: 8742771
    [No Abstract]   [Full Text] [Related]  

  • 10. Medications development for opioid abuse.
    Negus SS; Banks ML
    Cold Spring Harb Perspect Med; 2013 Jan; 3(1):a012104. PubMed ID: 23125072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications Development for Treatment of Opioid Use Disorder.
    Townsend EA; Negus SS; Banks ML
    Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 31932466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial.
    Badaras R; Jovaisa T; Lapinskiene I; Ivaskevicius J
    J Addict Med; 2020; 14(3):253-260. PubMed ID: 31609865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges to antagonist blockade during sustained-release naltrexone treatment.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Gossop M; Hegstad S; Kristensen Ø; Waal H
    Addiction; 2010 Sep; 105(9):1633-9. PubMed ID: 20707781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early outcomes following low dose naltrexone enhancement of opioid detoxification.
    Mannelli P; Patkar AA; Peindl K; Gottheil E; Wu LT; Gorelick DA
    Am J Addict; 2009; 18(2):109-16. PubMed ID: 19283561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
    Sinha R; Kimmerling A; Doebrick C; Kosten TR
    Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
    Elman I; D'Ambra MN; Krause S; Breiter H; Kane M; Morris R; Tuffy L; Gastfriend DR
    Drug Alcohol Depend; 2001 Jan; 61(2):163-72. PubMed ID: 11137281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.